Last update 21 Nov 2024

Phenazopyridine Hydrochloride

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryPhenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain. Its mode of action involves alleviating the discomfort associated with urinary tract infections, bladder inflammation, and other related maladies. The inception of phenazopyridine's use dates back to 1928 and, since then, it has burgeoned into a popular choice for individuals experiencing arduous urination or other urinary tract symptoms. It is crucial to note, however, that while phenazopyridine effectively mitigates pain, it does not remedy the underlying condition that engenders the discomfort. Thus, healthcare professionals must supervise phenazopyridine use as it may interact adversely with other medications and engender potential side effects.

Drug Type

Small molecule drug

Synonyms

2,6-Diamino-3-(phenylazo)pyridine, 2,6-Diamino-3-phenylazopyridine, 3-(Phenylazo)-2,6-pyridinediamine

+ [7]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesInfectious DiseasesOther Diseases

Active Indication

PainShock, Septic

Inactive Indication

BurnsDysuriaUrinary Incontinence+ [1]

Originator Organization-

Active Organization

University of Western OntarioKaren Pharmaceutical Co. Ltd.

Inactive Organization

Amneal Intermediate, Inc.

Pro Doc LtéeLaboratórios Osório de Moraes Ltda

Drug Highest PhaseApproved

First Approval Date

US (01 Jan 1928)

Regulation-

Structure

Molecular FormulaC11H12ClN5

InChIKeyQQBPIHBUCMDKFG-UHFFFAOYSA-N

CAS Registry136-40-3

View All Structures (2)

Clinical Trials associated with Phenazopyridine Hydrochloride

NCT06514430 / Not yet recruitingPhase 4IIT

Prophylactic Analgesia in Outpatient Intradetrusor onabotulinumtoxinA Injections: Efficacy and Feasibility of Alternative Pain Control Methods in a Diverse Urban Patient Population

The goal of this clinical trial is to learn more about using phenazopyridine (Pyridium) for pain control during bladder onabotulinumtoxinA ("botox") injections for surgical management of overactive bladder (OAB) for patients at Montefiore Medical Center in The Bronx. It will also learn about if using the phenazopyridine pill affects how satisfied patients are with their experience, how much pain patients feel afterwards, and if doctors think using the Pyridium pill affected how they performed the procedure. The main question it aims to answer is:
- Is oral phenazopyridine at least as good as intravesical lidocaine is for managing pain with bladder botox injections for OAB in Montefiore patients?
Researchers will compare phenazopyridine to intravesical lidocaine, a liquid put into the bladder, to see if phenazopyridine is at least as good at controlling pain with bladder botox injections as intravesical lidocaine is.
Participants will be assigned, by chance, to receive either the oral phenazopyridine pill or the intravesical lidocaine as their pain control for the procedure.

Start Date01 Dec 2024

Sponsor / Collaborator

Montefiore Medical Center

NCT06577493 / Not yet recruitingPhase 4IIT

Effectiveness of Phenazopyridine for Pain Following Urodynamics

The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.

Start Date15 Sep 2024

Sponsor / Collaborator

University of South Florida

CTRI/2024/06/068294 / Not yet recruitingPhase 3

A Randomized Double blinded Placebo controlled study to evaluate the efficacy of Phenazopyridine with Nitrofurantoin in patients with Urinary tract infection - NIL

Start Date15 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Phenazopyridine Hydrochloride

100 Translational Medicine associated with Phenazopyridine Hydrochloride

100 Patents (Medical) associated with Phenazopyridine Hydrochloride

314

Literatures (Medical) associated with Phenazopyridine Hydrochloride

01 Dec 2024·Clinical Pharmacology & Therapeutics

Medications and Acute Hemolysis in G6PD‐Deficient Patients – A Real‐World Study

Article

Author: Gronich, Naomi ; Rosh, Bar ; Saliba, Walid ; Stein, Nili

Many drug labels contain precautions of use in G6PD‐deficient patients due to hemolytic concerns, but much of this is based on scarce clinical, epidemiological, or structural data. In this real‐world study, we aimed to examine if the administration of presumably risky medications for G6PD‐deficient patients was followed by hemolysis. The study is based on data from Clalit Health Services database that provides inclusive health care for more than half of the Israeli population (~ 4.7 million). Within the database, we identified all G6PD‐deficient patients by G6PD <6 U/g Hb. Within the G6PD‐deficient cohort, we identified all hospitalizations with a discharge diagnosis of hemolysis (January 1, 2010 to December 31, 2022), validated the cases, and identified the culprit event. For the rest of the G6PD‐deficient patients with no‐hemolysis, we recorded filled prescriptions of medications listed as presumably risky. We identified 31,962 G6PD‐deficient patients. Within the cohort, there were 71 cases of major hemolysis requiring hospitalization (0.2% of the cohort), of whom 51 (71.8%) had been caused by ingestion of fava beans, six (8.5%) were associated with an infection, and three (4.2%) suggested to be associated with medications (nitrofurantoin, phenazopyridine, and a “pain killer”). Within the 31,875 patients with no major hemolysis, nitrofurantoin has been prescribed safely to 1,366 G6PD‐deficient males and females; hundreds/thousands of G6PD‐deficient patients had been prescribed safely ciprofloxacin, glibenclamide, ofloxacin, phenazopyridine, sulfamethoxazole/cotrimoxazole, sulfasalazine, hydroxychloroquine, glimepiride, mesalazine, and sulfacetamide. In this real‐world study, we are showing that a list of medications, suspected previously as carrying risks for hemolysis in G6PD‐deficient patients, have been prescribed safely to G6PD‐deficient patients, providing reassurance to patients, prescribers, and regulators.

14 Nov 2024·Blood

Oxidative hemolysis due to phenazopyridine in the absence of G6PD deficiency

Article

Author: Langer, Arielle L.

01 Nov 2024·BMJ Supportive & Palliative Care

Rare cause of dyspnoea: phenazopyridine-induced methemoglobinemia

Article

Author: Shekinah, Susan ; Sundararaj, Jenifer Jeba ; Joseph, Jewell ; Kamalakannan, Selvaguru

Methemoglobinemia, due to the oxidation of iron from ferrous to ferric form in the haemoglobin molecule, results in decreased oxygen delivery to the tissues. Phenazopyridine, a commonly used medication for urinary symptoms, is a rare cause of methemoglobinemia. We report an elderly woman with advanced vaginal cancer, who developed methemoglobinemia following the use of phenazopyridine at a dose of 200 mg three times a day for 14 days. She presented with dyspnoea without cyanosis, oxygen saturation of 70%, methemoglobin concentration of 32.2% in arterial blood gas analysis and haemoglobin of 5 g/dL. This condition was identified and treated with methylene blue and oxygen support, which resulted in complete recovery in two days. Though rare, this highlights the importance of ascertaining reversible causes of symptoms, even in palliative care settings. Medications as an aetiology of symptoms should be considered even if they were used on a long-term basis.

News (Medical) associated with Phenazopyridine Hydrochloride

31 Jan 2023

·www.prnewswire.com

Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio

North America will account for 35% of the global interstitial cystitis (IC) drugs market NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Interstitial Cystitis Drugs Market Company Profiles The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including: Amneal Pharmaceuticals Inc: The company offers interstitial cystitis and other related drugs such as Pyridium. Astellas Pharma Inc: The company offers interstitial cystitis drugs such as Rosiptor. Bayer AG: The company offers interstitial cystitis drugs such as Aleve and Aktion. Eli Lilly and Co: The company offers interstitial cystitis and other related drugs such as Tadalafil. Johnson and Johnson: The company offers interstitial cystitis drugs such as Elmiron. Kyorin Pharmaceutical Co. Ltd. Mission Pharmacal Co. Perrigo Co. Plc Pfizer Inc. Purdue Pharma LP Seikagaku Corp. To gain access to more vendor profiles available with Technavio, buy the report! Market Dynamics The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth. Competitive Analysis The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample Market Segmentation By type, the market is segmented into oral therapy and intravesical therapy. The oral therapy segment accounted for the largest share of the market. By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market. Related Reports: Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth. Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth. Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights What are the key data covered in this interstitial cystitis (IC) drugs market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of interstitial cystitis (IC) drugs market between 2023 and 2027 Precise estimation of the size of interstitial cystitis (IC) drugs market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of interstitial cystitis (IC) drugs market across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of interstitial cystitis (IC) drugs market vendors Browse for Technavio "Health Care" Research Reports Table of Content 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain analysis: Pharmaceuticals 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by Type 5.1 Market segments Exhibit 15: Type - Market share 2020-2025 (%) 5.2 Comparison by Type Exhibit 16: Comparison by Type 5.3 Oral therapy - Market size and forecast 2020-2025 Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million) Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%) 5.4 Intravesical therapy - Market size and forecast 2020-2025 Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million) Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%) 5.5 Market opportunity by Type Exhibit 21: Market opportunity by Type 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 24: Geographic comparison 7.3 North America - Market size and forecast 2020-2025 Exhibit 25: North America - Market size and forecast 2020-2025 ($ million) Exhibit 26: North America - Year-over-year growth 2020-2025 (%) 7.4 Europe - Market size and forecast 2020-2025 Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 28: Europe - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 30: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 32: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 33: Key leading countries 7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 36: Vendor landscape 9.3 Landscape disruption Exhibit 37: Landscape disruption Exhibit 38: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 39: Vendors covered 10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors 10.3 Astellas Pharma Inc. Exhibit 41: Astellas Pharma Inc. - Overview Exhibit 42: Astellas Pharma Inc. - Product and service Exhibit 43: Astellas Pharma Inc. - Key news Exhibit 44: Astellas Pharma Inc. - Key offerings 10.4 Bayer AG Exhibit 45: Bayer AG - Overview Exhibit 46: Bayer AG - Business segments Exhibit 47: Bayer AG - Key news Exhibit 48: Bayer AG - Key offerings Exhibit 49: Bayer AG - Segment focus 10.5 Johnson and Johnson Inc. Exhibit 50: Johnson and Johnson Inc. - Overview Exhibit 51: Johnson and Johnson Inc. - Business segments Exhibit 52: Johnson and Johnson Inc. - Key news Exhibit 53: Johnson and Johnson Inc. - Key offerings Exhibit 54: Johnson and Johnson Inc. - Segment focus 10.6 Novartis AG Exhibit 55: Novartis AG - Overview Exhibit 56: Novartis AG - Business segments Exhibit 57: Novartis AG - Key news Exhibit 58: Novartis AG - Key offerings Exhibit 59: Novartis AG - Segment focus 10.7 Perrigo Co. Plc Exhibit 60: Perrigo Co. Plc - Overview Exhibit 61: Perrigo Co. Plc - Business segments Exhibit 62: Perrigo Co. Plc - Key news Exhibit 63: Perrigo Co. Plc - Key offerings Exhibit 64: Perrigo Co. Plc - Segment focus 10.8 Pfizer Inc. 10.9 Seikagaku Corp. Exhibit 69: Seikagaku Corp. - Overview Exhibit 70: Seikagaku Corp. - Business segments Exhibit 71: Seikagaku Corp. - Key offerings Exhibit 72: Seikagaku Corp. - Segment focus 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 77: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 Viatris Inc. Exhibit 81: Viatris Inc. - Overview Exhibit 82: Viatris Inc. - Business segments Exhibit 83: Viatris Inc. - Key offerings Exhibit 84: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 85: Currency conversion rates for US$ 11.3 Research methodology Exhibit 86: Research Methodology Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Information sources 11.4 List of abbreviations Exhibit 89: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Phenazopyridine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D05450	Phenazopyridine Hydrochloride	G04BX06	DB01438

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	CN	Karen Pharmaceutical Co. Ltd.	01 Jan 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Incontinence	Phase 1	US	Amneal Intermediate, Inc.	01 Feb 2012
Burns	Phase 1	US	Amneal Intermediate, Inc.	01 Dec 2009
Dysuria	Phase 1	-	Laboratórios Osório de Moraes Ltda	01 Dec 2009
Pain	Phase 1	US	Amneal Intermediate, Inc.	01 Dec 2009
Urinary Tract Infections	Phase 1	US	Amneal Intermediate, Inc.	01 Dec 2009
Shock, Septic	Preclinical	GB	University of Western Ontario	01 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03755089 (Pubmed) Manual	Phase 4	Urinary Bladder, Overactive	100	phenazopyridine	(nstccwnknd): difference = -2.7 (95% CI, -11.3 to 10.7)	Negative	14 May 2022
				lidocaine
NCT02476448 (JET, CTgov)	Not Applicable	Ureteral Diseases	176	normal saline (Normal Saline)	pxapmgcyfl(uylawnudxt) = oemrjfnjft lwrsywyfuy (pcfwhepevg, iarzljtass - artbfegwnj) View more	-	23 Oct 2019
				Dextrose 10% (Dextrose 10%)	pxapmgcyfl(uylawnudxt) = vggnwqfffc lwrsywyfuy (pcfwhepevg, kvmumhltnh - atsbfygajv) View more
NCT02677623 (CTgov)	Phase 4	Ureteral Obstruction	140	Pyridium (A- Pyridium)	lcnpynzfzs(wrnljxkmvx) = uxyrhflxgc emxjvybtja (yevrlydnsc, idsgijjxsj - sazhxfptle) View more	-	30 May 2019
				Sodium Fluorescein (B- Sodium Fluorescein)	lcnpynzfzs(wrnljxkmvx) = ukjkexzimr emxjvybtja (yevrlydnsc, sraffrxgqy - kwcsidnglx) View more
NCT03065075 (Pubmed \| Female Pelvic Med Reconstr Surg)	Phase 3	Visceral Prolapse	152	Phenazopyridine 200 mg	ltcyflxtta(inhszubhya) = uvsdeczhca padnxgivug (vtoealxwdp )	Negative	26 Apr 2019
				No additional phenazopyridine	ltcyflxtta(inhszubhya) = ojjwpppety padnxgivug (vtoealxwdp )
NCT03065075 (EPOV, CTgov)	Phase 3	Uterine Prolapse \| Urinary Retention	152	Phenazopyridine (Phenazopyridine)	ckqqybdizk(rxwqisbklk) = qeszpahvuv ealvxwirgb (tpusrfievt, ylhsnsqedi - trvamajdxn) View more	-	26 Mar 2019
				Phenazopyridine (No Phenazopyridine)	ckqqybdizk(rxwqisbklk) = tcqdzlwael ealvxwirgb (tpusrfievt, mueptfbrwj - woldgnrjgk) View more
NCT02806713 (EPIPhANy, CTgov)	Phase 3	Urologic Diseases \| Pain, Postoperative	92	no Phenazopyridine (no Phenazopyridine)	cweqigpozk(qlwplwhjbr) = ejaqgqbole wvggjxnwgt (mchnijldqo, qtdnvxawhd - uamtftcddo) View more	-	05 Feb 2019
				Phenazopyridine (Phenazopyridine)	cweqigpozk(qlwplwhjbr) = lnwtadnapn wvggjxnwgt (mchnijldqo, fxuqxkagol - kdgpfmlykv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis